Clinical relevance of macromolecular complexes involving integrins, potassium and sodium ion channels and the sodium/proton antiporter in human breast cancer

Table 4 Association between hERG1, nNav1.5, hERG1/β1 and NHE1 expression and clinicopathological/molecular features. *: p<0.05 (Fisher exact test)

Clinical/molecular feature (number of patients)		hERG1 P value	hERG1/β1 P value	nNav1.5 P value	NHE1 P value
Molecular Subtype	Luminal A (23)	0.016* (Score 3 and Luminal A)	0.005* (Score 3 and Luminal A)	0.047* (Score 3 and Luminal B)	0.638
	Luminal B (20)
	HER2+(20)
	Basal-like (18)
Grading	G1(9)	0.023* (Score 2 and G2)	0.026* (Score 2 and G2)	0.052	0.086
	G2 (25)
	G3 (41)
TNM stage	I (52)	0.112	0.609	0.780	0.053
	II (18)
	III (10)
	IV (1)
Metastases	No (71)	0.477	0.822	0.152	0.461
Metastases	Yes (10)	0.477	0.822	0.152	0.461
Relapse	No (76)	0.427	0.353	0.214	0.538
Relapse	Yes (5)	0.427	0.353	0.214	0.538
ER	Negative (36)	0.001* (Score 3 and ER positive)	0.001* (Score 3 and ER positive)	0.002* (Score 2 and ER positive)	0.223
ER	Positive (45)	0.001* (Score 3 and ER positive)	0.001* (Score 3 and ER positive)	0.002* (Score 2 and ER positive)	0.223
PgR	Negative (40)	0.005* (Score 3 and PgR positive)	0.001* (Score 3 and PgR positive)	< 0.001* (Score 3 and PgR positive)	0.192
PgR	Positive (41)	0.005* (Score 3 and PgR positive)	0.001* (Score 3 and PgR positive)	< 0.001* (Score 3 and PgR positive)	0.192
HER2	Negative (28)	0.020* (Score 2 and HER2 Score 1)	0.009* (Score 3 and HER2 Score 1)	0.141	0.599
	Score 1 (9)
	Score 2 (15)
	Score 3 (29)
Ki67	≤ 20% (23)	0.131	0.078	0.250	0.061
Ki67	> 20% (58)	0.131	0.078	0.250	0.061

ISSN: 1475-2867